The Passing of Senator John McCain

Statement from ASCO President Monica M. Bertagnolli, MD, FACS, FASCO
For immediate release
August 31, 2018

Contact

Aaron Tallent
(571) 483-1371

Senator John McCain will lie in state in the U.S. Capitol Building today. The following ASCO statement pays tribute to his life-long service to our country​.

“The American Society of Clinical Oncology (ASCO) mourns the passing of Arizona Senator John McCain from glioblastoma multiforme (GBM). During his more than 30 years in Congress, Senator McCain represented a bipartisan spirit and a commitment to his country that will be truly missed.

“Senator McCain advocated for many issues of importance to ASCO and its members, including Food and Drug Administration regulation of tobacco products, interoperability of electronic health records, and medical research supported by the National Institutes of Health. A survivor of recurring melanoma, he was also steadfast in raising awareness on the importance of wearing sunscreen to prevent skin cancer whenever he could. His struggle with GBM, an aggressive form of brain cancer, is a painful illustration of the need for critical research that will accelerate progress against this disease.

“ASCO extends its deepest sympathy to Senator McCain’s family and will continue to work with Congress to carry out his legacy of building consensus on issues impacting our nation.”

About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.